Calithera Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Calithera Biosciences sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).

22 total trials none currently recruiting 14 completed early-phase tilt top decile by trial count

Calithera Biosciences: 22 sponsored US clinical trials, none currently recruiting.

Calithera Biosciences sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor and Lymphoma Malignancies, with 1 trials.

Top-decile sponsor footprint

Calithera Biosciences ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

14 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

22 total, page 1 of 1

TERMINATED Phase 2

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05319028
TERMINATED

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04698681
TERMINATED Phase 2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
COMPLETED Phase 1

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

NCT04279769
COMPLETED Phase 1

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NCT03965845
TERMINATED Phase 1

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

NCT03875313
COMPLETED Phase 2

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217
COMPLETED Phase 1

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

NCT03357627
TERMINATED Phase 2

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03123393
COMPLETED Phase 2

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

NCT03163667
COMPLETED Phase 2

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

NCT03057600
COMPLETED Phase 1

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

NCT02944435
TERMINATED Phase 1

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

NCT02834247
TERMINATED Phase 1

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

NCT02771626
COMPLETED Phase 2

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

NCT02756364
TERMINATED Phase 1

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

NCT02323113
COMPLETED Phase 1

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

NCT02197572
COMPLETED Phase 1

Study of the Glutaminase Inhibitor CB-839 in Leukemia

NCT02071927
COMPLETED Phase 2

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

NCT02049957
COMPLETED Phase 1

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

NCT02071888
COMPLETED Phase 1

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

NCT02071862
COMPLETED Phase 1

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

NCT02000934

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 8

Therapeutic Areas

Advanced Solid Tumor and Lymphoma Malignancies 1
Clear Cell Renal Cell Carcinoma 1
Advanced Solid Tumors 1

How the Calithera Biosciences early-phase archive is shaped

22 indexed studies, none listed as recruiting (0% open); 14 completed (64%).

Phase mix: 0 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumor and Lymphoma Malignancies (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Calithera Biosciences: archived-pipeline peers nationwide

Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Calithera Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15% Total trials Recruiting share Calithera BiosciencesAlaunos TherapeuticsAlexza PharmaceuticalsFate TherapeuticsGriffin Hospital10xBio22nd Century Group23andMe3-C Institute for Social Development
Calithera Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Calithera Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 22 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Calithera Biosciences page

22 registered trials is a research-attention snapshot, not an endorsement of Calithera Biosciences or any single study.

  • None of Calithera Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Advanced Solid Tumor and Lymphoma Malignancies is the condition Calithera Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor and Lymphoma Malignancies trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Calithera Biosciences pipeline card: 22 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.